LGND - Latest News
Ligand Pharmaceuticals Incorporated (LGND), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $4.43B. Trailing twelve-month P/E ratio is 28.64. Beta to the broader market is 1.07.
The article list below shows the most recent LGND headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent LGND Headlines
Ligand Pharmaceuticals Q1 Earnings Call Highlights
marketbeat.com - May 8, 2026
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation
Ligand Reports First Quarter 2026 Financial Results
globenewswire.com - May 7, 2026
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
globenewswire.com - May 6, 2026
NEW HOPE, Pa. , May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc.
Ligand to Participate in May Investor Conferences
globenewswire.com - May 5, 2026
JUPITER, Fla. , May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team wi
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
globenewswire.com - May 5, 2026
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations.
How News Affects LGND Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track LGND's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked LGND news questions
- What is the latest LGND news headline?
- The most recent LGND headline (May 8, 2026) is "Ligand Pharmaceuticals Q1 Earnings Call Highlights". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the LGND news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What LGND news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual LGND options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.